Featured Studies

Researchers are enrolling people with locally advanced or metastatic cancer who are prescribed atezolizumab (alone or with other approved treatments). The study will monitor blood levels to adjust infusion schedules, aiming to see if lower or less frequent doses can be given without reducing effectiveness, over a period of up to 2 years.

Investigators at the National Cancer Institute (NCI) are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.